Human CXCL9/MIG Antibody, InVi
vo Block/Neutralizing Antibody-Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody- 询价
- Biogradetech
- 美国
- BGT-ANT-37324
- 2025年07月12日
- ELISA,In vivo Neutralization
- Mouse
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
免疫原详情见datasheet，该抗体亚型为：IgG2a, kappa
- 保存条件：
-2°C-8°C
- 保质期：
1年
- 库存：
100
- 供应商：
艾美捷科技
- 宿主：
Mouse
- 应用范围：
ELISA,In vivo Neutralization
- 抗体英文名：
Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody
- 抗体名：
Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody
Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody，Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody，Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody,Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody
产品名称：Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody-Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody
产品货号：BGT-ANT-37324
产品规格：100ug#1mg
应用类型：ELISA,In vivo Neutralization
蛋白别名：CMK, HuMIG, Monokine induced by interferon-gamma, Small-inducible cytokine B9, C-X-C motif chemokine 9, MIG, CXCL9, SCYB9, Gamma-interferon-induced monokine
Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody-Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody详情见产品datasheet
点击：Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody-Human CXCL9/MIG Antibody, InVivo Block/Neutralizing Antibody更多Biogradetech产品信息价格，货期，产品说明，百度搜“艾美捷科技”进入官网网站，查看具体产品且快速下单。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验1). Albumin or powdered milk is used to block the remaining sites which could result in false positives. Monoclonal antibodies will react with the antigen attached to the microtiter plate. The complex antigen-antibody is then reacted with enzyme conjugates
. MTT assay is used for the detection of cellular proliferation. Cytokine Bioassays Using Neutralizing mAbs (eBioscience) Antibodies that block binding of cytokines to their specific receptors and neutralize their effects are critical
neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Preprint at bioRxiv 11: Lynch, KL et al. (2020) Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Preprint
技术资料暂无技术资料 索取技术资料
